 EMERYVILLE, Calif., March 04, 2022 GLOBE NEWSWIRE -- Zogenix Nasdaq: ZGNX, a global biopharmaceutical company developing and commercializing rare disease therapies, announced that new data from the companys research and development program for FINTEPLA fenfluramine in Lennox Gastaut syndrome LGS will be presented at the hybrid American Academy of Neurology AAN Annual Meeting 2022, in-person in Seattle April 2-7 and held virtually April 24-26. 